Low-level arsenic exposure in water linked to increased heart disease risk

The FDA on Fri­day grant­ed full ap­proval to Seagen and Astel­las Phar­ma’s Pad­cev (en­for­tum­ab ve­dotin-ejfv) in com­bo with Mer­ck’s Keytru­da (pem­brolizum­ab) for pa­tients with lo­cal­ly

Off-the-shelf cell ther­a­py biotech Cata­ma­ran Bio made a “re­cent de­ci­sion to com­mence wind-down,” CEO Alvin Shih told End­points News in an email on Mon­day. The